Silence Therapeutics appoints Thomas Christely

pharmafile | September 21, 2011 | Appointment | Research and Development appointment, research and development 

UK-headquartered biotech Silence Therapeutics has appointed Thomas Christély as chief executive.

He was instrumental in the merger of Silence Therapeutics AG (formerly Atugen AG) with Silence Therapeutics plc (formerly SR Pharma plc), having joined Atugen AG in 2001 as chief financial officer.

He subsequently served as chief operating officer from 2002 before being appointed chief executive in 2006.

Advertisement

Prior to this Thomas was senior VP and chief financial officer at OXO Chemie AG, a Swiss pharmaceutical company, and founded its subsidiary OXO Chemie Inc. in San Francisco, where he stayed from 1997 until 2000

He will be based at Silence’s facility in Berlin.

Jerry Randall, chairman of Silence Therapeutics, said: “Now that Silence has become a wholly European company it is appropriate to have a chief executive based in Europe.

“Thomas’ experience with the team and the science will ensure continuity as we move forward. We are confident that Thomas has the vision, expertise and experience necessary to move the Company toward the achievement of its corporate and clinical objectives.”

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content